The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
AACR 2024 | Upcoming studies investigating linvoseltamab in myeloma
Faith Davies, MD, MRCP, MRCPath, FRCPath, NYU Langone Medical Center, New York, NY, briefly outlines the upcoming studies investigating linvoseltamab in patients with multiple myeloma (MM). The LINKER-MM1 trial (NCT03761108) assessed the agent in patients with triple-class refractory disease. New trials will move it into earlier lines of therapy and the newly diagnosed setting, both alone and in combination with transplant. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
